HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hypertrophic cardiomegaly — Clinical Guidelines

Overview

Hypertrophic osteoarthropathy (HO) is a syndrome characterized by digital clubbing, periostitis, and joint effusions, often associated with underlying malignancies or other systemic diseases. 3 4

Diagnosis

Clinical Features: Digital clubbing, arthralgia, periostitis, and joint swelling. 3 4

Imaging: Radiographic findings of periosteal reaction and joint effusions. 3

Physical Examination: Presence of clubbing and characteristic joint findings. 3

Differential Diagnosis: Inflammatory arthritis, chronic infections, and other causes of clubbing. 3

Management

First-Line Treatments:

- Chemotherapy: For malignancy-associated HO, initial management often involves addressing the underlying malignancy. 5 - Pain Management: High-dose opioids, NSAIDs, and corticosteroids. 5

Adjunctive Treatments:

- Local Radiotherapy: Effective for palliation of severe pain in refractory cases. 5 - Removal of Pathogenic Sources: Surgical intervention, such as removal of a Celestin tube, can lead to regression. 6

Special Populations

Comorbidities: Management strategies may need adjustment in patients with advanced malignancies or complex social circumstances affecting symptom control. 4 5

Key Recommendations

Address Underlying Cause: Prioritize treatment of the underlying malignancy or systemic disease to manage HO symptoms effectively. (Evidence: Strong 5)

Utilize Local Radiotherapy for Refractory Pain: Consider local radiotherapy as an effective adjunctive therapy for severe, treatment-resistant pain in HO. (Evidence: Moderate 5)

Evaluate for Surgical Interventions: In cases where HO is secondary to identifiable surgical sources (e.g., Celestin tube), removal may lead to clinical regression. (Evidence: Weak 6)

References

1 Buhalog B, Moustafa F, Arkin L, Lee K, Siwy K, Donelan M et al.. Ablative fractional laser treatment of hypertrophic burn and traumatic scars: a systematic review of the literature. Archives of dermatological research 2021. link 2 Khalid A, Baqai MT. Primary hypertrophic osteoarthropathy. JPMA. The Journal of the Pakistan Medical Association 2014. link 3 Pineda C, Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheumatic diseases clinics of North America 2013. link 4 Molto A, Marini C, Neuenschwander H. Lessons from an Ukrainian woman with clubbing and back pain. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2004. link 5 Yeo W, Leung SF, Chan AT, Chiu KW. Radiotherapy for extreme hypertrophic pulmonary osteoarthropathy associated with malignancy. Clinical oncology (Royal College of Radiologists (Great Britain)) 1996. link80045-8) 6 Haslock I, Vasanthakumar V. Disappearing hypertrophic osteoarthropathy. British journal of rheumatology 1988. link

Hypertrophic cardiomegaly